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Abstract
Background: Associating liver partition with portal vein ligation for staged-hepatectomy
(ALPPS) is a technique for inducing accelerated hypertrophy in patients with insufficient
future liver remnant (FLR). It remains unknown whether this hypertrophy may lead to rapid
cancer cell dissemination and/or alteration of immune cell/function reconstitution in the
FLR. We aimed to determine if the rapid hypertrophy during ALPPS procedure results in
more circulating tumour cell (CTCs) dissemination and whether the FLR remains
immunologically competent in patients with CRLM.
Methods: In our prospective, observational, 2-arm study, we assessed the utility of CTCs
as an evaluation tool for disease dissemination. Moreover, mucosa-associated invariant T
(MAIT) cells were used as a marker of liver immune competency of the FLR in patients
undergoing to ALPPS (Arm-1) or single stage liver resection (Arm-2; control) from July
2015-June 2016. Blood samples and liver tissue were collected at different time points.
CTCs were measured by the CellSearch System. CTC positivity was defined as > 1 CTCs
in a 7.5-ml blood sample. Frequency of MAIT cells were measured in both groups (blood,
liver and tumour) using flow cytometry.
Results Among 24 potential patients, 17 met the criteria and underwent curative hepatic
resection: 7 in Arm-1 and 10 in Arm-2. Baseline demographics were similar between
groups. In stage-1 ALPPS, CTCs were present in two patients (28.6%), one of whom
continued to be positive after completion of both stages, whereas four patients (44.4%) in
Arm-2 were positive, p=0.289. Patients with positive CTCs (one each-Arms) at follow up
developed early recurrence and died, p=0.0083. In addition, we found a trend towards an
increase in MAIT cells within the liver in Arm-1 compared to Arm-2 (28 %vs17.42%;
respectively), (p=0.067), and within the tumor (17.42%vs10.42%, respectively, p=0.308).
I

Conclusion: Accelerated and extensive liver hypertrophy during ALPPS was not
associated with CTC dissemination. Persistent positivity of CTCs at follow-up was
significantly associated with disease progression and cancer-related death. Presence and
upward trend in the frequency of the MAIT cells in the ALPPS group suggest immune cell
restoration in the FLR. Nevertheless, given the small sample size, a larger cohort is needed
to validate these findings.
Keywords: Circulating tumor cells (CTCs), Associating liver partition with portal vein
ligation for staged hepatectomy (ALPPS), colorectal liver metastases (CRLM), CellSearch
System, the mucosa-associated invariant T (MAIT) cells.
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CHAPTER 1
1. INTRODUCTION
1.1. Colorectal Cancer Incidence
Colorectal cancer (CRC) represents the third most common cancer world-wide with
about ~1.4 million new cases in 2012 and the fourth leading cause of death, ~700,000
annually (8.5%). (1,2) The countries with the highest incidence rates are Australia, New
Zealand, Canada, the United States, and some countries in Europe such as the UK; whereas
China, India, Africa, and South America have the lowest incidence. (1,3) In Canada, CRC
is the second most common type of cancer among males (13.9%), and the third most
common type of cancer in females (11.5%), representing the third most common overall
types of cancer (12.7%). (4)

1.2. Colorectal Liver Metastases (CRLM)
The liver is a common site for hematogenous metastases from CRC. (5–8) Up to a
fifth of patients with primary colorectal carcinoma have synchronous hepatic metastases,
and nearly half of patients who undergo resection of their primary CRC will develop with
will develop metachronous liver metastases at some time during the course of their
disease.(9)

1.3. Treatment
1.3.1. Systemic Treatment for CRLM
The outcome of untreated colorectal liver metastases (CRLM) has been well
documented in the literature. (6,10) The median survival of untreated synchronous CRLM
is just 5 to 10 months, and 3-year survival is very unusual, limited only to those patients
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who initially have solitary liver metastases arising in a metachronous manner.(6) Over the
past 3 decades, 5-fluoracil (5-FU) has been used either alone or in the combination with
other regimens for the treatment of colorectal liver metastases. (6,11) The tumor response
rates with 5-FU alone are reported to be 10-15%, and can reach up to 30-39% when
Leucovorin (LV) is added. The median overall survival (OS) with 5-FU alone is reported
to be ~12.6 months, improved to 14.8 months when combination therapy is used. (6,11)
Currently, with the development and improvement of new chemotherapy regimens
such as irinotecan (FOLFIRI) and oxaliplatin (FOLFOX), the tumour response rate has
improved from 22% to ~ 50%, allowing these therapies to emerge as the first line regimen
for treatment of stage IV colorectal cancer (CRC).(5,6,12) The overall survival outcomes
reported using these regimens has been superior to single agent therapy (19.5 months versus
15 months) (11) without a significant difference with respect to patient tolerance or toxicity.
Overall survival following FOLFIRI and FOLFOX treatment is similar at 21.5 and 20.6
months respectively. (11,13) The FOLFOX regimen is complicated by an elevated rate of
neurotoxicity and neutropenia, while FOLFIRI therapy is associated with other symptoms
such as nausea, vomiting, mucositis, and alopecia. (6,11)
Other therapies have emerged to target growth factors or cell surface receptors
involved in colorectal cancer liver metastases biology. These biological therapies might
stabilize disease and improve patient disease-free survival by causing tumour necrosis.
(11,12) Bevacizumab (Avastin), is a monoclonal antibody against vascular endothelial
growth factor (VEGF), approved to be used in combination with 5-FU as first-line
chemotherapy for patients with CRLM. These regimens have demonstrated a higher tumour
response rate and longer patient overall survival, when compared to therapies without
Avastin therapy, 44.8 vs 34.8% and 20.3 vs 15.6 months, respectively. (12) Moreover,
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additional monoclonal antibody therapies such as cetuximab and panitumumab have also
shown benefit for tumors with KRAS mutation by improving the response rate and patient
survival. (14)
In summary, modern systemic chemotherapy has improved outcomes for metastatic
CRC treatment and plays an important role in the absence of resection (median survival
~18 to 20 months) (11). However, notable and superior results are achieved when
combined with liver resection (5-year survival ~55-67%). (15)
1.3.2. Surgical Management of CRLM
During the last 3 decades, hepatic surgical treatment has evolved and become the
gold standard for patients with primary or metastatic liver malignancies. Moreover, the
actual role of the multidisciplinary tumour board committees in the management of this
complex group of patients, with the aim of surgical resection has achieved the most
satisfactory results, benefiting the overall course of the patient during the disease process.
(5,6,16). The actual 5-year survival following a margin-negative hepatic resection with the
combination of chemotherapy treatment is ~ 40-70%, with 10-year survival approaching
20%. (6,17,18) Recurrence and progression is reported in 70–80% patients undergoing
surgery. (5) In addition, the notable ability of the liver to regenerate after hepatic resection
has enabled aggressive surgical approaches in patients with insufficient hepatic reserve.
Resectability criteria for CRLM patients have been widely revised and expanded
over the last 15 years. (5) Previous clinic pathological parameters such as number or
metastases, presence of extra-hepatic disease or width of resection margin are no longer
used to exclude patients from consideration for surgical resection. (5–7) The current hepatic
resection criteria should be defined by: the preservation of vascular inflow, vascular
outflow, and biliary drainage, with the objective of preserving an adequate future liver
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remnant (FLR). Those patients with extensive liver disease or borderline liver parenchyma
reserve should undergo a technique to increase the volume of their FLR such as portal vein
embolization (PVE), two-stage hepatectomy, or a chemotherapy modality to downsize the
disease and convert the liver tumor burden into resectable disease.(5)
As described in the literature, for the best outcomes, surgical resection should only
be considered if the following criteria are met: (6–8,19)
1. Adequate patient health performance condition (normal baseline lung, heart, kidney
and liver function).
2. Primary tumour resectable or already resected.
3. Absence of extra-hepatic disease, or if present and localized, disease is planned for
resection (e.g. lung metastases).
4. Solitary nodule or multiple nodules technically feasible for liver resection (attempt
to get negative resection margins “R0”).
5. Vascular inflow and outflow with adequate biliary drainage in the remaining liver
must be preserved.
6. Adequate volume/function of the FLR after resection (at least 20% of the total FLR
if normal parenchyma and 30-70% when a history of chemotherapy or underlying
liver disease is present).(19,20)
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1.3.2.1. Future Liver Remnant (FLR)
Over the past two decades, there has been an inclination to expand what is defined
as “resectable” disease, pushing the boundaries and leaving a narrow line between complete
success and liver failure. Therefore, development of new multidisciplinary modalities has
been explored to improve the resectability rate while avoiding catastrophic post
hepatectomy liver failure (PHLF). Reports recommend an estimated FLR to body weight
ratio of greater than 0.5 to avoid liver failure. (20,21)
To achieve an adequate volume of the FLR after resection and thus, decrease the
risk of developing PHLF, patients with normal liver parenchyma or undergoing a short
course of chemotherapy (< 12 weeks) usually require a FLR of at least >20 %, while a FLR
>30-60% is needed for patients after >12 weeks of chemotherapy, steatosis or hepatitis, and
a FLR > 40-70% is mandatory in the presence of underlying liver disease (e.g. cirrhosis,
cholestasis depending on the degree of underlying hepatic dysfunction). Thus,
chemotherapy duration and adequate FLR volume are the critical determinants of hepatic
reserve which directly affect morbidity and mortality following hepatic resection for
CRLM. (20–23)

1.3.2.2. Techniques to increase the FLR
During the last 40 years, several surgical and non-surgical techniques have emerged
in order to increase the size of the FLR and avoid PHLF, in those patients with primary and
metastatic liver cancer undergoing to extensive liver resection. Examples of these
procedures are: portal vein occlusion (either by embolization or ligation), two staged
hepatectomy, and ALPPS (Associating Liver Partition with Portal Vein Ligation for Staged
Hepatectomy). (7,8,13,24)
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1.3.2.2.1. Portal Vein Occlusion (PVO)
Makkuchi et al. introduced the use of portal vein embolization (PVE) in the early
1980s as a non-surgical technique to stimulate hypertrophy of the FLR before extensive
liver resections. (25) Currently, two methods of portal vein occlusion (PVO) can be applied
and are considered as standard therapy for patients with unilobar disease and insufficient
FLR: either radiologically by portal vein embolization (PVE) or surgically by portal vein
ligation (PVL). The PVO technique has been shown to increase the size of the FLR from
8% to 27% over an interval of 2-8 weeks, depending on the underlying liver disease.
Unfortunately, these same hypertrophy results have been difficult to replicate at other
centers. PVO is safe, with a complication rate of 5-8%(19). However, its main
disadvantages include insufficient hypertrophy of the FLR and disease progression after
the PVO, preventing curative liver resection in 20-30% of patients. (26)

1.3.2.2.2. Two-Stage Hepatectomy:
The concept of two-stage hepatectomy was introduced in the early 2000s. (26) This
surgical hepatic technique was designed for patients with primarily bilobar unresectable
liver metastases, which typically cannot be resected in a single stage while preserving an
adequate FLR. The strategy of the two stage hepatectomy is to attempt a curative resection
through a sequential approach. The goal of the first stage is to clear the future liver remnant
by removing the highest number of metastases, making the second hepatectomy feasible
and potentially curative after proper FLR regeneration. (26) Thus, a two-stage hepatectomy
offers the potential of disease free survival to patients that otherwise would have a poor
outcome. Patients who undergo a two-stage hepatectomy with combination chemotherapy
have a 3-year survival rate of 35% and a median survival of 31 months. (5,26) Nevertheless,
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initial experience without PVE was associated with high incidence of PHLF from
insufficient functional volume of the FLR a high mortality rate of 9-15%. (5,27)

1.3.2.2.3. Two-Stage Hepatectomy with PVO
Liver failure due to insufficient functional liver volume of the FLR represents the
main cause of postoperative mortality in patients undergoing two-stage hepatectomy. Thus,
the combination of PVO (either PVE or PVL) and staged hepatectomy was proposed as a
modality to induce compensatory hypertrophy of the FLR.(27–29) After introduction,
initial reports showed no operative mortality, low postoperative morbidity (~ 15 to 30%),
and 1-and 3-year overall survival rates of 70% and 54%, respectively. (5,27) Nevertheless,
insufficient liver regeneration of the FLR and tumor progression during the long waiting
period (6-8 weeks) was again the biggest limitation, making this procedure only feasible in
70% of the cases. (30)

1.3.2.2.4. Associating Liver Partition with Portal Vein Ligation for Staged
Hepatectomy (ALPPS)
During a planned extended right hepatectomy for a perihiliar cholangiocarcinoma,
ALPPS was created by chance in 2007. Due to insufficient FLR, the right portal vein was
ligated to induce hypertrophy of the left lateral segment of the liver, after the liver
parenchyma had already been transected. On postoperative day 8, abdominal computed
tomography imaging showed extensive hypertrophy of the left lateral segment prompting
the decision to complete the resection of the right liver. (23) Therefore, the new technique
consisted of adding a liver parenchymal partition during the first stage of a two-staged
hepatectomy, facilitating an inter-stage time of only 1 week.
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The initial experience of this innovative technique was presented in 2011 during the
European Hepato-Pancreato-Bilairy meeting held in South Africa.(30) Soon after, during
the inaugural study in 2012, the authors reported their experience in 25 patients. Initially
the procedure was named as “two-staged extended right hepatectomy with initial surgical
exploration, right PVL, and in situ splitting” (22), and later renamed with the acronym
“ALPPS” (Associating Liver Partition with Portal Vein Ligation for Staged
Hepatectomy).(31)

1.3.2.2.4.1. ALPPS Results Worldwide:
Since the first description of the ALPPS procedure, refinements to both the
technique, and patient selection criteria have been explored. The most promising results
have been reported in the field of CRLM, and thus, establishing the main indication for
ALPPS to be when metastases are primarily unresectable due to a very small predicted
FLR. (7,8,30,32) Other indications to consider are in specific situations such as
hepatocellular carcinoma (HCC) or cholangiocarcinoma, if resection is oncologically
possible .(7)
In terms of volumetric growth, rapid liver regeneration remains the main advantage
of ALPPS: total liver volume growth of FLR is reported around 50-84% in 1 week and 120200% after 14 days. (7,32,33) Nevertheless, principle limitations are related to high
morbidity (53–90%), high mortality (0–28%), and no reports on long-term oncologic safety
and outcome.(8) The largest studies from the ALPPS registry report the procedure has a
97% feasibility rate with a morbidity rate of 44%, and 90-day mortality rate of 811%.(33,34) From the oncological standpoint, long-term outcomes with respect to the
disease free and overall survival are areas that need further investigation.
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1.3.2.2.4.2. ALPPS Results at the London Health Sciences Centre
The first ALPPS procedure in Canada was performed in London, Ontario at the
London Health Sciences Centre (LHSC) in April 2012 by Dr Roberto HernandezAlejandro. (35) Ever since, LHSC has been the pioneer and leader overall in North
America. Despite the high morbidity and mortality earlier described, (30) refinements in
the technique and a better understanding of patient selection has been paramount to success
at our institution, in addition to our strict selection criteria: patients with colorectal liver
metastases (CRLM), extensive bilobar CRLM necessitating an extended hepatectomy, a
technically feasible resection (planned R0), a predicted FLR <30%, no evidence of extrahepatic disease, good functional capacity defined as ECOG (Eastern Cooperative Oncology
Group) 0 or 1, and complete or partial tumour response after 6-cycles of neo-adjuvant
therapy assessed by the Response Evaluation Criteria In Solid Tumors (RECIST). (35)
Furthermore, we have paid special attention to the improvement of the surgical
technique by maximizing the preservation of the middle hepatic vein and minimizing the
dissection of the hepatoduodenal ligament to avoid ischemia and congestion of segment 4
and to decrease the potential for ischemic injury to the biliary tree. Taken together, these
points might explain our lower morbidity rate (14%) and postoperative 90-day mortality
rate (0%) compared with other centers.(35) To date, our center has already performed 34
ALPPS procedures and our latest data shows a 1-year OS of 84% and 3 years OS of 55%
(median 1264 days), as well as 1-year DFS of 71%, and 3-year DFS of 36%. (Figures 1
and 2)
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Figure 2. ALPPS Disease-Free Survival, LHSC: LHSC 2012-2016
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1.4. Liver immunology
The liver is considered the largest solid organ in the body involved in nonimmunological activities such as metabolic functions, nutrient storage, and detoxification.
Also, it is a place of complex immunological properties, such as induction of
immunological tolerance and innate immune responses, which are possible through the
production of diverse acute phase proteins, complement components, cytokines and
chemokines, and by different populations of resident immune cells.(24,36,37)
The liver functions impressively as an important filter for gut contents and blood
systemic circulation via the Porto-systemic interface (70-80% of the liver blood supply
comes from the portal vein, with the remaining 20-30% from the hepatic artery). As a low
pressure blood system, liver venous blood flows in close contact with the hepatic sinusoids.
Hepatocytes compose ~60-80% of overall liver cells (38). Their main role is in metabolism,
and production of 80–90% of the circulating innate immunity proteins in the body.(6)
Moreover, the liver capillary microenvironment consists of different specialized cells (liver
sinusoidal endothelial cells [LSEC], intravascular liver resident macrophages “Kupffer
cells”, and liver dendritic cells) which have an important role in initiating and organizing
hepatic immune responses.
The liver immunological homeostasis mechanism is not fully understood yet. The
narrow balance between tolerance and liver immunity is controversial. Classical examples
of tolerance can be observed in viral hepatitis infections, metastatic cancer (most commonly
from colorectal cancer), and transplantation. On the other hand, undesirable immune
responses may ensue, for instance, in the case of autoimmune hepatitis, primary sclerosing
cholangitis (PSC), and primary biliary cirrhosis (PBC). (6,37) Figure (3)
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Moreover, the liver has essential immune and metabolic roles that are described and
summarized in Figure 4. The following sections will provide a basic understanding of the
immunological mechanisms orchestrated by the liver, and focus on the role of those liver
cells that are implicated in tumour immune surveillance (liver lymphoid cell population).
In particular, the role of the “Mucosal-associated invariant T (MAIT) cells” will be
discussed.

1.4.1. Human liver cell distribution
The liver contains most of the cellular elements of the innate and adaptive
immunity. Their frequency and distribution are observed in Figure 5. (39) Each of them
has a specific role and effector function, either cytotoxic or regulatory, capable of killing
pathogens or suppressing the immune response. Also, differentiation into cells that can
produce different cytokines and antibodies, IFN (interferon), IL (interleukins), TGF
(transforming growth factor), TNF (tumor necrosis factor) can be observed, which has an
important role during antitumor surveillance. (6,39)

14

Figure 3. Liver Tolerance vs Immunity (6):

Figure 3. Image representing liver tolerance vs immunity. The liver has tolerogenic
characteristics observed in diseases such as viral hepatitis, metastatic cancer and transplantation.
On the opposite side, the liver exhibits a high immune response: autoimmune hepatitis, PSC and
PBC. From Jarnagin WR, Blumgart LH, 2012: Blumgart´s surgery of the liver, biliary tract and
páncreas. 2-Volume set. 5E ed. Copyright 2012,2007,2000,1994,1998 by Saunders, and imprint
of Elsevier Inc.
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1.4.2. Antigen-Presenting Cells:
Antigen-presenting cells (APCs) are important in orchestrating or shaping the
adaptive immune response. The three most important APC cells are Kupffer cells, LSEC,
and dendritic cells. They play a crucial role in the maintenance of tolerance balance on noninflammatory scenarios. The liver APC cells function in capturing and presenting antigens
to T cells. The success of their activation and response, depends directly on the proper
molecular co-stimulation. If co-stimulation is successful, proliferation and development of
effector T cells will occur, with subsequent release of cytokines. In contrast, if costimulation is unsuccessful T cell death or anergy will result. (6,38–40)

1.4.3. Dendritic cells (DCs), liver sinusoidal endothelial cells and Kupffer cell
(KCs)
Liver DCs are known as the most potent APCs of the immune system (Figure 6,7).
They play an essential role in the antigen capture and subsequent presentation to the
immune effector cells. Liver DCs travel from the portal circulation through the space of
Disse, finally exiting via lymphatic circulation. Their essential function involves immune
regulation, bridging, and adaptive immunity. Nevertheless, liver DCs show tolerogenic
characteristics, promoting the production of anti-inflammatory IL-10, which has a
suppressive function. (24,37,38)
Liver sinusoidal endothelial cells work as sentinels, and are important during
pathogen detection. Their structure in the form of multiple fenestrations selectively allows
the passage of antigens through the LSEC to the hepatocytes, establishing close contact
among antigens and hepatocytes. This characteristic promotes organ homeostasis, blood
detoxification, and inflammatory response regulation.(6,37)
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Figure 4. Liver immunological & metabolic roles (37) :

Figure 4. Metabolic and immunological roles of the liver. The liver has an important role in
inflammatory regulation via production of clotting factors and acute phase proteins, antigen
presenting T cells and anti-microbial proteins. In addition, it has important metabolic roles
including lipid metabolism, glycogen storage production, protein production, and others. From
Robinson MW, 2016: Liver immunology and its role in inflammation and hemeostasis. Cell Mol
Immunol 13:267-76. Copyright 2016, CSI and USTC.
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Figure 5. Healthy liver cell distribution.

Hepatocytes
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Endothelial
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Figure 5. Distribution and frequency of parenchymal and non-parenchymal healthy
human liver cells. From Racanelli V,2006: The liver as an immunological organ.
Hepatol Baltim MD 43:S54-62. Copyright 2006, The American Association for the
Study of Liver Diseases.
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Liver Kupffer cells originate from monocytic precursors and correspond to the
largest group of macrophages in the body. Their phagocyte function and strategic location
allow them to travel from the periportal area to the space of Disse, with subsequent
elimination of endotoxins and apoptotic hepatocytes. (6,38,39)

1.4.4. Liver Lymphoid Immune Cell Population
The liver lymphoid cell population is composed of T cells, natural killer cells (NK
cells), and B cells. (37,39) The main characteristics of these cells include potent cytokine
production and mediating the innate and adaptive immune response of the liver. In addition,
they contribute to the removal of infected, injured or malignant cells. A subpopulation
arising from T cells comprises conventional T cells (CD8+ and CD4+), which identifies
antigens in the context of major histocompatibility complex (MHC) class I and II.
Typically, CD8+ is higher in proportion to CD4+ (2:1) in the liver, whereas their frequency
is inverted in the blood. Unconventional T cells correspond to another subtype of T cells.
These are integrated of natural killer T cells (NKT cells), which have a restricted T receptor
and recognizes antigens only in the case of MHC I (molecule CDI d), and TCRγδ T cells,
that identifies a very limited proportion of antigens.(6,36,37,39)

1.4.5. Natural Killer Cells
Human NK cells comprises most of the lymphocyte liver population and play an
important role during liver inflammation, particularly in antiviral defense. Traditionally,
NK cells are categorized as either CD56-low-expressing cells with cytolytic activities,
CD56-high-expressing with immune-modulatory cytokine-producing cells, and CD49a,
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which mainly release high proportions of CD69, granzyme B, interferon-γ (IFNγ), tumour
necrosis factor-alpha (TNF-alpha), and granulocyte macrophage colony-stimulating factor
(GM-CSF).(24,36,41)
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Figure 6. Innate immune liver elements:

Figure 6. Image representing the microvascular hepatic anatomy. Liver sinusoidal endothelial cells
shield and divide hepatocytes from sinusoidal blood flow by the “Space of Disse” flow. In addition,
DC, KC, NKT cells, NK cells can be found and have close contact with the microcirculation, and
had a subsequent specific function in the inflammatory response.
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Figure 7. Liver immune response.

Figure 7. Schematic representation of the adaptive immune response illustrating inflammatory
activation, from antigen-presenting cells to T and B cells leading to signaling, costimulation and
cytokine production with subsequent effector function, From Jarnagin WR, Blumgart LH, 2012:
Blumgart´s surgery of the liver, biliary tract and páncreas. 2-Volume set. 5E ed. Copyright
2012,2007,2000,1994,1998 by Saunders, and imprint of Elsevier Inc.
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1.4.6. Natural Killer T cells (NKT cells)
NKT cells are a specific subgroup of T cells, whose main role is to regulate the
immune responses in the environment of autoimmunity, cancer, and microbial infection,
through the expression of different cytokines such as interleukin-4 (IL-4) and IFNγ. In the
cancer context, tumour-infiltrating human NKT cells express CD56, CD69, and proinflammatory cytokines such as TNF-alpha and IFNγ, showing an important antitumor
role.(41,36,37)

1.4.7. MAIT cells
The study of mucosal-associated invariant T (MAIT) cells in humans is an emerging
field in immunology. Human MAIT cells are known as a subset population of conventional
T cells, which are localized preferentially in liver and intestinal mucosa, composing ~3050% of the liver lymphocytes and 10-15% of the peripheral blood lymphocytes.(42)
Circulating and tissue-infiltrating human MAIT cells express a semi-invariant T cell
receptor (TCR) of Vα7.2-Jα33 alpha chain rearrangement (CD161 or IL 18Rα) and respond
to MHC I like molecule MR1 (MHC-related protein 1). (42–44)
Emerging experimentation has shown that activated MAIT cells can display
different cytokines such as interleukin-17A (IL-17A), IFN-γ, and TNF-αlpha. (42,43,45)
As a subset of the innate-like T cells, MAIT cells produce an arsenal of cytotoxic effector
molecules and pro-inflammatory cytokines that play an important function in defense
against infectious pathogens (bacteria and yeasts, but not viruses). (43,46,47) In addition,
they play a role in inflammatory diseases and wound healing by their quick reactivity to
bacterial infection and injury. (43,46,47) These distinguishing characteristics have
prompted the immunology community to question their potential role in certain
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circumstances such as cancer. Despite this, yet we know next to nothing about their role in
immune surveillance against tumor formation in the liver. Recent evidence has suggested
that they may have potential clinical relevance for patients with colorectal cancer.(44)
Moreover, further investigations demonstrate their peculiar ability to persist through
chemotherapy and xenobiotics secreted by the gut bacteria (42), due at least in part to
their high levels of ABCB1 expression, which works as a multidrug efflux protein
transporter to remove toxic compounds from the cytoplasm.(42,43)

1.4.7.1. MAIT Cells in Colorectal Cancer
Results presented in early 2016 by a group from China (44) suggest that MAIT cells
accumulated and infiltrated in CRC tumour tissue, and thus might play an important role in
immune surveillance against CRC patients (Figure 8). Their study showed that the
frequency of circulating activated/memory MAIT cells was lower compared with the levels
observed in the tumour tissue. Furthermore, serum carcinoembryonic antigen (CEA) levels
were found to be highly associated with the rate of infiltrating MAIT cells and negatively
associated with the rate of circulating active/memory MAIT cells. In fact, high levels of
TNF-α, IFN-γ, IL-2 and IL-17 were positively associated with TCRValpha7.2Jalpha33
mRNA in cancer tissues.(44) This data supports that high levels of infiltrating
activated/memory MAIT cells in the tumour tissues might represent anti-tumor immunity
against CRC, so, use as a potential biomarker for testing the severity and prognosis of CRC
should be considered. Also, some reports demonstrated an important association between
IFN-γ levels in the setting of T cell immunity against CRC through p53 modulation to
induce tumor cells apoptosis (45), whereas, other studies show an associaciation between
IL-17 expression in the tumor and worse prognosis in patients with CRC. (48)
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In the present investigation, we further evaluate MAIT cells in terms of their role
on hepatic immune surveillance against colorectal liver metastases in patients undergoing
liver resection.

25

Figure 8. Hypothetical MAIT cell role during CRLM.

Figure 8. Schematic representation of the hypothetical role of MAIT cells during colorectal liver
metastases.
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1.5. Circulating Tumour Cells (CTCs)
Cancer metastasis is the principal cause of death in patients with cancer, and
dissemination of tumour cells into the systemic blood circulation is an essential step.
Therefore, early identification of this dissemination sequence is crucial for monitoring and
impeding metastatic disease. The mechanisms by which circulating cancer cells
disseminate from the tumour to the blood circulation is an area under intensive
investigation. (49–52)

1.5.1. Natural History of Metastases from Colorectal Cancer
Tumor metastasis can be defined as a series of biological processes whereby tumor
cells from the primary neoplasm migrate to a distant location.(9,49,52) (Figure 9 ) Invasive
CRC cells can metastasize through two pathways:
1. Regional lymph nodes ® through central lymphatics ® the systemic circulation.
2. Portal venous drainage ® Liver.
Circulating tumour cells (CTCs) are defined as a group of cells that are shed from
primary tumour and from metastatic deposits into the blood circulation.(49,53) CTCs are
found in the blood of patients with many cancers, however, their presence is extremely
infrequent in healthy people.(49,52) The use of CTCs as prognostic and predictive tumour
markers has been explored in patients with metastatic cancers such breast (54–57), prostate
(58,59) and colorectal (60,61) carcinoma. On the basis of these studies, the number of CTCs
(≥5 for breast/prostate; ≥3 for colorectal) were predictive of progression-free survival (PFS)
and overall survival (OS). Moreover, the analysis of CTCs at different time-points during
treatment has been shown to be useful for determining treatment efficacy and therapy
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response. These promising findings suggest that CTCs may represent a “liquid biopsy” that
could inform clinical decision-making, potentially allowing for the discontinuation of
ineffective chemotherapy regimens earlier than current practice, thereby avoiding
morbidity due toxicity and enabling a change to other potentially more beneficial treatment
options. (54,58)
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Metastatic colonization includes the following process:
1. Tumor cells invade the tissue surround the primary tumor.
2. “Invasion” into either the lymphatics or blood circulation.
3. Intravasion ® Extravasion ® Growing ® Angiogenesis.

3

2
1

Figure 9. Schematic representation of biological process of metastatic colorectal dissemination.
The term ‘colonization’ is used herein to reflect the combined influences of tumor cell
proliferation, apoptosis, dormancy and angiogenesis in the formation of a progressively growing
lesion in a distant site.(9)
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Multiple methods for CTC enrichment and identification have emerged during the
last decade, either label-dependent such as immunomagnetic, where the main target has
been epithelial cell adhesion molecule (EpCAM), or label-independent enrichment based
on size or density. Other approaches characterize CTCs by immunocytochemistry, using
PCR approaches or mRNA/DNA sequences. Additionally, others can detect viable tumour
cells or tumor-specific chromosomal abnormality (Figure 10). (49,62–64)

1.5.2. CellSearch System
Originally developed by Immunicon, the CellSearch system (Janssen Diagnostics,
Raritan, NJ, USA) is the first and currently the only method clinically approved assay by
the Food and Drug Administration (FDA) for capturing and enumerating CTCs in advanced
breast, prostate and colorectal cancer.(54,55,59,60,64)
The epithelial cell adhesion molecule (EpCAM) is a cell adhesion molecule
overexpressed in many carcinomas and has been used as a marker for CTC enrichment.
The CellSearch is a semi-automated system based on immunomagnetic technology that
isolates and enumerates CTCs by targeting EpCAM-positive cells. Through this approach,
CTC numbers have been correlated with disease free survival and overall survival in
primary and metastatic carcinoma. (54,56,57,59,60) Due to its reported clinical evidence,
high reliability, and FDA clearance, we chose the CellSearch system as a method for CTC
detection in this research study.
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CTC enrichment and identification approaches for CTCs (63):

Figure 10. Schematic representation of different strategies to separate and capture circulating
tumour cells: label-dependent and label-independent methods. Immunomagnetic based methods
focusing on EpCAM protein are the most common used among label-independent CTC
enrichment methods. From Joosse SA, 2015: Biology, detection and clinical implications of
circulating tumor cells. EMBO Mol Med 7:1-11. Copyright The Authors.
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1.5.3. Use of CTCs in Colorectal Malignancies
Novel technology platforms using immunomagnetic separation have permitted the
accurate identification, isolation, enumeration, and characterization of CTCs from many
epithelial carcinomas. (49,52,64–66) In a multicenter study, Cohen et al reported, that
patients with colorectal liver metastasis had unfavorable survival prognosis when levels of
CTCs of CTCs were ³ 3 in 7.5 ml of blood, and showed that this was an independent
predictor of inferior disease free survival and overall survival in patients with colorectal
liver metastases. (60)
These results provide a promising basis from which to investigate different
scenarios of the applicability of CTCs in colorectal cancer patients; including screening in
earlier stages of colorectal cancer, evaluation of treatment response and analysis of
progression during the time off chemotherapy (Figure 11). Recent studies have also
evaluated the impact of the presence of CTCs at the time of liver resection in metastatic
colorectal cancer. (2,67–69) A Norwegian group reported the association between positive
CTCs and high recurrence rate in patients with colorectal liver metastases undergoing twostage hepatectomy, suggesting another potential utility for postoperative CTC
assessment.(2) This current study will assess the utility of measuring the number of CTCs
as an evaluation tool of disease progression using the CellSearch system in patients with
colorectal liver metastases undergoing for liver resection; either ALPPS or single stage
liver resection.
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Pathways of circulating tumour cells in patients with colorectal cancer (62):

Figure 11. Diagram showing the pathway of CTCs, through the mesenteric-porto-systemic
circulation in colorectal cancer patients. Circulating tumour cell (red cells) flows from the
primary tumour to the systemic blood, then are captured using the CellSearch system technology.
From Deneve e, 2013: Capture of viable circulating tumor cells in the liver of colorectal cáncer
patients. Clin Chem 59:1384-92. Copyright American Association for Clinical Chemistry. (62)
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CHAPTER 2
2.

RATIONALE, HYPOTHESES, AND STUDY OBJECTIVES
2.1. Rationale
Since the first description of ALPPS procedure, refinements to both the technique

and patient selection criteria have been developed. ALPPS has been demonstrated to be a
valid treatment option in selected patients who were previously considered unresectable,
especially in those with colorectal liver metastases.(7,30,35,70) Nevertheless, several
important aspects of the procedure remain unknown, including long-term oncological
outcomes. Moreover, concerns arise with respect to the impact of this rapid hypertrophy in
the liver microenvironment, in particular related to potential repercussions for tumour
biology and disease progression. In addition, the immunological composition of the liver
during the ALPPS approach and whether the rapid hypertrophy of the FLR is accompanied
by equally rapid immune cell/function reconstitution remains essentially unexplored.
Circulating tumour cells are defined as a group of cells that are shed from primary
tumour and metastatic deposits into the blood circulation.(49,53) Their use as a prognostic
and predictive tumour marker has been explored in patients with colorectal liver metastases
(60,61). On the basis of these studies, the number of CTCs (≥3/7.5 mL blood) were
predictive of inferior disease free survival and overall survival in patients with colorectal
liver metastases. Moreover, the analysis of circulating tumour cells at different time points
during the treatment was useful to determine treatment efficacy and therapy response, thus
supporting the use of this novel biomarker as a tool for decision making before liver
resection in patients with CRLM. This study aims to investigate the utility of measuring
the number of circulating tumour cells as an evaluation tool of disease progression using
the CellSearch system in patients with colorectal liver metastases undergoing two stage
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hepatectomy; ALPPS or single stage liver resection.
The liver represents a specialized immunological environment that promotes
tolerance in normal conditions, but also contains immune cells that can potentially combat
cancer. While tumor-specific T cells are detectable in many cancer patients including those
with primary liver cancers or liver metastases, they typically fail to eradicate cancer. The
liver harbors many natural killer T (NKT) cells that constitute an attractive therapeutic
target for adjuvant immunotherapy of cancer. In addition, the liver is highly enriched in
mucosa-associated invariant T (MAIT) cells, which can comprise up to 50% of all hepatic
lymphocytes; yet we know next to nothing about their role in immune surveillance against
tumors forming in the liver. MAIT cells express an arsenal of cytotoxic effector molecules
as well as pro-inflammatory cytokines (interferon [IFN]-gamma, interleukin [IL]-17)
known to favor antitumor immunity. It is currently unclear whether MAIT cells infiltrate
tumor masses in the liver.(42,45) Due to these characteristics mentioned, it has prompted
the immunology community to hypothesize on their potential role in certain circumstances,
such as cancer. In the present investigation, we further explore the role of MAIT cells, in
terms of immune surveillance against colorectal liver metastases in patients undergoing
liver resection.

2.2. Hypotheses
We hypothesize that an elevation of ≥3 CTCs/7.5 ml in the blood will indicate
disease progression during the rapid liver hypertrophy in patients with colorectal liver
metastases. Moreover, we believe that the presence of MAIT cells with their cytotoxic
effector molecules and pro-inflammatory cytokines such as (interferon [IFN]-gamma,
interleukin [IL]-17) in the future liver remnant will represent the immunological
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competency of the liver during the rapid liver regeneration process in ALPPS patients with
colorectal liver metastases. Finally, we predict that chemotherapy will not affect the liver
immune functions.

2.3. Objectives
1. To determine if rapid hypertrophy in colorectal liver metastases induces disease
progression.
2. To determine if the liver in patients with colorectal liver metastases undergoing ALPPS
is immunologically competent.
3. To identify if chemotherapy affects the liver immune response in patients with
colorectal liver metastases undergoing for liver resection.
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CHAPTER 3
3. Methodology
3.1. Experimental Design
We designed a prospective, observational, 2-arm feasibility study assessed the
utility of blood biomarkers of cancer progression (Circulating tumour cells, “CTCs”), and
immunological competency of the liver (MAIT cells) in patients with colorectal liver
metastases (CRLM) undergoing ALPPS (Arm 1) or single stage liver resection (Arm 2;
control).
Up to 10 eligible patients per arm were accrued from the London Health Science
Centre-University Hospital (LHSC-UH) and the London Regional Cancer Program
(LRCP). Sample size was determined based on the pilot nature of the study and our
demonstrated ability to recruit ~14 eligible ALPPS patients/year. (35)
Ethics approval for this study was obtained from the Western University Research
Ethics Board for Health Sciences Research Involving Human Subjects (Approval number:
REB106937; Appendix 1) and the Lawson Health Research Institute (R-15-360). All work
involving the use of human samples was done in accordance with ethics guidelines
approved by the institutional research ethics review board at Western University. Subjects
were provided a letter of consent outlining the study details and informed written consent
was obtained.

3.1.1. Patient inclusion criteria:
•

Male and female patients over 18 years of age

•

Confirmed diagnosis of colorectal liver metastasis (CRLM)
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•

Systemic chemotherapy treatment response

•

No evidence of extra-hepatic metastatic disease

•

Intent for curative liver surgery treatment
Technically feasible resection (planned RO)

3.1.1.1. Specific inclusion criteria for ALPPS (Arm 1):
•

Diagnosis of CRLM with predicted future liver remnant less < 30%

•

Extensive bilobar CRLM necessitating an extended hepatectomy

•

Good functional capacity (Eastern Cooperative Oncology Group [ECOG] 0 or 1)

•

Complete or partial response to systemic chemotherapy after 4-6 cycles evident by
CEA and radiology

•

Consented for ALPPS

3.1.1.2. Specific inclusion criteria for single stage liver resection (Arm 2):
•

Diagnosis of CRLM with predicted future liver remnant more than > 50 %

•

Single or oligo CRLM consented for single stage resection

3.1.2. Exclusion Criteria:
•

Age more than 75 or less than 18 years

•

ASA risk score more than 3

•

Eastern Cooperative Oncology Group (ECOG) score 2 or more

•

End-stage liver disease
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3.2.

Chemotherapy treatment

All patients in this study were reviewed by a multidisciplinary tumor board
(consisting of HPB and colorectal surgeons, medical oncologists, radiation oncologists,
pathologists, and radiologists). Following discussion, the consensus recommendation of the
multidisciplinary tumour board was followed regarding liver surgical approach and type of
neo-adjuvant treatment regimen. The choice of chemotherapy regimen was based on
tumour load, tolerance, and comorbidities by the multidisciplinary tumour board. Tumour
responses and progression were classified with the use of the Response Evaluation Criteria
in Solid Tumour (RECIST) after 4 cycles.(71)

3.3. Surgical technique
The technical aspects of single or two staged hepatectomy “ALPPS” have been
previously described (Figures 12-14). (7,8,72–74) Major liver resection was defined
according to the Brisbane 2000 terminology (resection of ³ 3 segments of the liver ). (75)
Single staged hepatectomy was performed in all patients with curative intent with
predicted future liver remnant (FLR) more than ³ 50 %, whereas ALPPS was performed in
those patients with predicted FLR < 30 % that met full inclusion criteria. In both scenarios
a general laparotomy was performed to rule out extrahepatic disease, an intraoperative
ultrasound was performed to assess the technical resectability and presence of metastases
not visualized prior to surgery. The liver was mobilized according to the location of the
tumour and segments to be respected. (7)
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The technical aspects of ALPPS procedure are summarized in two major surgical
stages and one interval phase. The key points of stage-1 include complete mobilization with
ligation and division of the retro-hepatic veins draining into the inferior vena cava (IVC),
tumour clearing of the FLR if disease was present in the FLR, right portal vein ligation with
hepatic arterial flow preservation and biliary drainage of the deportalized liver (DL), and
liver in situ split of the parenchyma between the FLR and deportalized liver. After sufficient
growth of the FLR is obtained (generally within 7 to 10 days) measured by volumetric
computed tomography (CT) volumetric, a stage-2 procedure was completed with a right
trisectionectomy by a transection of the right hilar plate, as well as transection of the right
and middle hepatic veins followed by the removal of the DL.
Complications were scored according to the Dindo-Clavien grading system. (76)
Minor complication was defined as a complication grade £ II, major complication as a
grade ≥ IIIa, and severe complications as grade ≥IIIb.
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Figure 12. Representation of extensive metastatic bilobar disease from colorectal cancer patients.
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Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy
“ALPPS” concept, surgical technique description:

7-10
Days

Figure 13. Stage 1 ALPPS: (A) Clearing of the future liver remnant (resection of CRLM in
segment II and III of the liver) (B) portal vein ligation in order to redirect the portal blood
flow through the FRL with preservation of the right hepatic artery; (C) parenchymal
transection along the deportalized liver and future liver remnant. Following by 7-10 days
until FLR growing.
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Figure 14. (A) Inter-stage ALPPS: volumetric liver of the FLR is reassessed at day 7-10 by abdominal
computed tomography for enough hypertrophy; (B) Stage 2 ALPPS: ALPPS finalized with an extended
right hepatectomy, keeping a growth FLR.
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3.4.

Circulating tumour cells (CTCs)

Blood samples (7.5 ml) were collected by routine phlebotomy, and measured at the
following endpoints:
•

Arm 1: baseline (pre-chemotherapy), pre- stage 1 ALPPS, inter-stage ALPSS, post
2 stage ALPPS and prior to re-starting chemotherapy (follow-up). (Figure 15)

•

Arm 2: baseline (pre-chemotherapy), pre-resection surgery (single stage liver
resection), 3-4 days’ post-resection surgery and prior to re-starting chemotherapy
(follow-up). (Figure 16)

3.4.1. Blood sample preparation for CellSearch® platform analysis
Samples were collected into CellSave blood collection tubes (Janssen Diagnostics),
which stabilize CTCs for 96 hours at room temperature. 1 x 10 ml sample per patient was
collected at each time point. Blood samples were analyzed for the presence and number of
CTCs using CellSearch® platform (Janssen Diagnostics) located in the clinical flow
cytometry facility at LHSC. An automated and standardized immunomagnetic cell
enrichment of CTCs in blood samples (7.5. ml) was carried out using antibodies targeting
epithelial cell adhesion molecule (EpCAM), and subsequent labeling with fluorescent
antibodies specific for epithelial cells (CK 8,18, and 19), DAPI, and leukocytes
(CD45/DAPI). Samples were imaged using the CellSearch Analyzer II, and CTCs were
identified by two trained (independent and blinded) reviewers based on positive CK
staining, negative CD45 staining, cell size (> 4um), cell morphology (round to oval), and
staining with the DNA stain 4’, 6-diamino-2-phenylindole (DAPI).
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Figure 15. ARM 1: ALPPS group, with the sequential description of the time-points, where the CTCs
blood samples and the liver tissue with respect to the MAIT cells were taken.
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Figure 16. ARM 2: Single stage liver resection group, with the sequential description of the time-points,
where the CTCs blood samples and the liver tissue with respect to the MAIT cells were taken.
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3.4.2. Circulating tumour cell data analysis
CTCs # at each time point were categorized as being either unfavourable (≥3 CTCs)
or favourable (<3 CTCs) as defined previously. (60) The relationship between CTC # and
clinical outcome was investigated and were observed and compared during the rapid liver
regeneration process and the single liver resection. (Objective 1)

3.4.3. Statistical analysis
The distribution of continuous variables was tested for normality using the ShapiroWilk test. Continuous variables with normal distributions were express as mean (± standard
deviation) and were compared using the independent sample t-test. Variables with nonnormal distributions were expressed as median (interquartile range) and were compared
using the Mann-Whittney-U test. Categorical variables were compared using the Fisher’s
exact test. Statistical significance was accepted at p< 0.05. Data was analyzed using SPSS
20 (IBM SPSS, Chicago, IL., USA).

3.5. Mucosa-associated invariant T (MAIT) cells
For the immunological studies, liver tissues and blood samples were collected from
each Arm of the study at the time of the surgery. (Figure 15 and 16)
3.5.1. Human peripheral blood mononuclear cell isolation
Peripheral blood was collected prior to administration of anesthesia in 5 x standard
heparinized BD vacutainers (BD Biosciences, San Jose, CA, USA) for a maximum volume
of approximately 50mL). Following collection, whole blood was diluted 1:1 in 2% Fetal
Calf Serum (FCS) /PBS and applied to a Ficoll-Paque Plus (GE Healthcare Life Sciences,
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Mississauga, ON, CAN) gradient in 50mL SepMate tubes (Stem Cell Technologies) and
processed at room temperature as per the manufacturers protocol. Following isolation, cells
were resuspended in complete RPMI and seeded at approximately 1x106 cells/well in
200µL, and indicated stimuli were added in a volume of 50µL for a total volume of 250µL
per well.

3.5.2. Human liver mononuclear cell isolation
During the surgical resection, a 1-5 g sample of healthy liver tissue and 1-5 g sample
of tumour tissue were collected in saline in a 15 mL tube and placed on ice. Samples were
taken to the laboratory of Microbiology & Immunology located in the SDRI building at
Western University. Immune function and profiling experiments were undertaken to
determine the status of the immune cells residing within and distal to the tumour, and within
the healthy liver tissue as well.
Following collection, liver tissue was cut into small pieces using a razor blade, after
which they were pushed through a 400 µM filter and washed with 2%FCS/PBS. Collected
cells were spun at 400Xg for 5 minutes, the supernatant decanted, and the pellet washed
with an additional 50 mL 2% FCS/PBS. Following the second wash, cells were applied to
a 33% Percoll Plus (GE Healthcare Life Sciences, Mississauga, ON, CAN) mixture and
spun for 12 minutes at 700Xg (no brake). Following the spin, the supernatant was
discharged and the mononuclear cells were isolated from the pelleted fraction. Following
isolation, cells were resuspended in cRPMI and plated at approximately 1x106 cells/well in
200µL, and indicated stimuli were added in 50 µL of media for a total volume of 250µL
per well.

48

3.5.3. In vitro stimulation
Recombinant IL-12 (Peprotech, Quebec, CAN) and IL-18 (Peprotech, Quebec,
CAN) were used at a concentration of 5 ng/mL for the in vitro activation of isolated MNCs.
The bacterial superantigen staphylococcal enterotoxin B (SEB) was used at 100 ng/mL.
Isolated MNCs were plated at 10x106cells/mL and left untreated or stimulated with a
combination of recombinant IL-12 (rIL-12) and rIL-18, SEB, or Klebsiella pneumoniae
lystate for 24 hrs. For the last 5 hours, a combination of 1 µM brefeldin A (BFA) (SigmaAldrich) and 2 µM monensin (eBioscience) was added to the cells.

3.5.3.1. Staphylococcal Enterotoxin B (SEB)
Recombinant SEB was generated using an approved institutional biosafety protocol
adhering to the Public Health Agency of Canada regulations. SEB was cloned from S.
aureus (strain COL), expressed in BL21 (DE3) competent Escherichia coli (E. coli), and
purified by nickel column chromatography.

3.5.3.2. Preparation of Klebsiella lysate
A stock of Klebsiella pneumoniae lysate was generated by growing a Klebsiella
pneumoniae clinical isolate, Parkwood-18 (a gift from Dr. Miguel Valvano (Queen’s
University Belfast, Belfast, United Kingdom)), overnight in Luria broth at 37°C. Following
overnight culture, the culture was washed three times with cold PBS and the OD600 adjusted
to 6.5. Cells lysis was achieved by subjecting the cells to a pressure at 30,000 pounds per

49
square inch (PSI) for 5 min to induce membrane rupture. The resulting lysate was stored at
-80°C until use. The lysate was at 1:50 for in vitro cell stimulatio
3.5.4. Flow cytometry
Cells were labeled using various panels of anti-human antibodies, as has previously
been described.(77) Cells were then stained extracellularly with a panel of anti-human
antibodies at 4°C cells diluted in 2%FCS/PBS. After 30 minutes, cells were washed 3 times
with 2 mL of 2% FCS/PBS. In cases of intracellular cytokine, 5 hrs prior to the end of
culture a mixture of BFA diluted 1:10000 and Monensin A diluted 1:1000 (eBioscience)
were added to the cultures to allow for the intracellular accumulation of cytokines.
Additionally, for intracellular antigen or transcription factor analysis determination,
following extracellular staining cells were re-suspended in 150 µL cytofix/permeabilization
buffer (eBioscience) and left at room temperature in the dark for 20 minutes. Following
fixation, cells were washed with 100 µL of 1x Permwash (eBioscience) and re-suspended
in 100 µL of a panel of intracellular antibodies diluted in 1x Permwash. In the case of
transcription factor determination, the foxP3 transcription factor permeabilization kit was
used (eBioscience) in place of the standard intracellular cytofixation kit. A BD FACSCanto
II flow cytometer and FlowJo v9 software (Tree Star, Ashland, OR, USA) were used for
data acquisition and analysis.
Human MAIT cells were defined as CD3+ Va7.2+ CD161high. Briefly our gating
strategy was as follows: From total PBMCs, lymphocytes (defined by their forward and
side scatter properties) were gated and divided into CD3+ and CD3-. Of the CD3+ cells,
MAIT cells were defined as CD3+ Va7.2+ CD161high, while conventional T cells were
considered CD3+ Va7.2-. For specific analytic analysis (i.e. cytokine, transcription factor
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expression, granzyme, etc.), appropriate isotype controls were used when determining the
gate locations. Unless otherwise stated, antibodies were obtained from eBioscience. Va7.2
-PercpCy5.5 and granzyme A - Alexa 700 were obtained from Biolegend (San Diego, CA,
USA).
3.5.5. MAIT cells data analysis
Comparison of the MAIT cells present within and outside metastatic lesions in
terms of their frequency and function (i.e. IFN- and IL-17 production) within the peripheral
blood and liver were performed. Moreover, we evaluated the liver immunological
competence regarding the activity of the MAIT cells among patients undergoing for rapid
hypertrophy (ALPPS) and single liver resection was also made. (Objective 2)
A correlation between the type of chemotherapy and the activity of the MAIT cells in the
peripheral blood and the liver was performed in order to analyze the effect of the
chemotherapy into the liver immune response in both groups. (Objective 3)

3.5.6. Statistical analyses
Statistical assessments were made with the aid of GraphPad Prism 6 software.
Comparisons were performed using Student’s t-test or ANOVA, as appropriate, and
differences with p<0.05 were deemed significant. *, **, *** and **** denote p<0.05,
p<0.01, p<0.001 and p<0.0001, respectively.
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CHAPTER 4
4. RESULTS
The objectives of the current study were to determine if the rapid hypertrophy that
occurs during ALPPS induces disease progression, to evaluate if the liver of ALPPS
patients was immunologically competent, and to investigate whether chemotherapy affects
the liver immune response in patients with colorectal liver metastases undergoing for liver
resection; either ALPPS or single stage hepatectomy.
In our prospective, observational, 2-arm feasibility study we were able to assess the
utility of CTCs as an evaluation tool of disease progression and the immunological
competency of the liver through analysis of MAIT cells in patients with colorectal liver
metastases undergoing to ALPPS (Arm 1) or single stage liver resection (Arm 2; control).
In the present investigation (From August 2015 to June 2016), 24 patients were recruited
for the study and 17 patients full met our study criteria; 7 patients in Arm 1 (ALPPS group)
and 10 patients in Arm 2 (Single stage liver resection group). Patient selection and
management flow chart is shown in Figure 17.
Patient characteristics from the 17 patients that completed liver resection are
summarized in Table 1. Median follow up was 139 days (interquartile [IQR] range 46 to
379 days). All patients completed follow-up evaluation to assess CTCs at time point 4 (12 month after surgery). Demographic characteristics were comparable in both groups,
including age, gender and body mass index. Preoperative risk index was also similar in
both groups.
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Flow chart of the 24 patients recruited in the study for CTC and MAIT cells

Figure 17. Flow chart summarising the 24 patients recruited in the study for investigation of CTCs and
MAIT cells in patients with CRLM undergoing for curative liver resection treatment, either; ALPPS (ARM1)
or single staged resection (ARM2). Seven patients completed both stages in ARM 1, while 10 patients
completed single staged resection in ARM 2.
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TABLE 1. TRANSLICH STUDY POPULATION CHARACTERISTICS
ARM 2
ARM 1
SINGLE STAGE
VARIABLE
ALPPS
LIVER
N= 7
RESECTION
N= 10
Demographics
Age, (years) µ
57 ± 4
55± 3
Male Gender [n(%)]
6 (85%)
4 (40%)
BMI (Kg/m2) µ
25 ± 2
24.7 ± 1.3

p= 0.05

0.598
0.134
0.969

ASA operative risk, n(%)
<3
>3

2 (29%)
5 (71%)

6 (60%)
4 (40%)

Primary tumour location, n (%)
Colon
Rectum

7 (100%)
0

7 (70%)
3(30%)

Stage of primary disease, n (%)
T-4
T-3
T-2

3 (43%)
3 (43%)
1 (14%)

4 (40%)
6 (60%)
0

0.434

Lymph Nodes Positive

4 (0-18)

0.5 (0-8)

0.183

Grade, n (%)
High grade
Low grade

2 (29%)
5 (71%)

1 (10%)
9 (90%)

0.536

6 (85%)
4 (40%)
4 (2-9)
45 (20-200)
25 (17-150)

8 (80%)
4 (67%)
3 (2-8)
34.5 (10-86)
27(10-49)

1..0
0.608
0.599
0.215
0.43

Metastatic tumour disease, n (%)
Synchronous
Bilobar tumour involvement
Number of lesions
Size, largest lesion (mm) before chemotherapy
Size, largest lesion (mm) after chemotherapy

0.334
0.227

0.047
Carcinoembryonic Antigen (CEAµ,mL)
23 (23-80)
4 (1-4220)
Continues variables are expressed as median (IQR). Abbreviations: µ, mean; Kg, Kilograms,
BMI, body mass index

54

4.1. Demographics Characteristics
4.1.1. Primary Tumor Characteristics
Primary tumour location was as follows: Arm 1; 100% of the patients had the
primary tumour in the colon, and Arm 2; 70% (7 patients) had the primary tumor in the
colon and 30% (3 patients) in the rectum, p= 0.334. Based on the TNM score classification
for malignant tumours, the primary cancers in both Arms were comparable (Table 1).

4.1.2. Metastatic Tumour Disease
Synchronous metastatic disease was present in 6 patients (85%) in Arm 1 vs 8
patients (80%) in Arm 2, p= 1.0. Bilobar tumour involvement was observed in 4 patients
(57%) in Arm 1 compared to 4 patients (40%) in the Arm 2, p= 0.608. The median number
of liver metastatic lesions in Arm 1 was 4 (interquartile range [IQR] 2-9) and 3 in Arm 2
(2-8), p= 0.599 (Table 1).
The median size of the largest lesion (mm) before chemotherapy treatment was 45
mm (20 mm-200 mm) in Arm 1 and 34.5 mm (10 mm-86 mm) in Arm 2, p=0.215. After
chemotherapy treatment, there was a decrease in the median size of previous largest lesion;
25 mm (17 mm-150 mm) in Arm 1 and 27 mm (10 mm-49 mm) in Arm 2, p= 0.430 (Table
1).
The levels of Carcinoembryonic Antigen (CEA µ mL) before chemotherapy
treatment was significantly higher in the Arm 1, 23 (23-80) compared to Arm 2, 4 (1-4220),
p=0.0478 (Table 1).
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4.1.3. Chemotherapy Characteristics
Of the 17 patients that underwent liver resection, all received neo-adjuvant
chemotherapy treatment. Patients received either single regimen with FOLFOX or
combined regimen FOLFOX or FOLFIRI with Bevacizumab. Most of the patients in Arm
1 had combined regimen 5/7 (71%), while most of the patients in the Arm 2 had single
regimen with FOLFOX 7/10 (70%), p= 0.095. The median number of chemotherapy cycles
was 6 (5-11) in Arm 1 vs 5 (1-7) in Arm 2, p=0.439. The median time off (days)
chemotherapy prior liver resection was 50 days (32-72 days) in Arm 1 and 51 days (27-184
days) in Arm 2, p=0.830 (Table 2). Of the 7 patients in Arm 1, 6 (86%) showed
radiologically chemotherapy response, compared to 7 of 10 patients (70%) in Arm 2,
p=0.338 (Table 2).

4.1.4. Surgical approach
One patient in Arm 1 (14%) underwent an extra hepatic simultaneous resection (low
anterior resection, LAR), whereas 3 patients (30%) in Arm 2 (2 patients had LAR and 1
patient had an abdominal perineal resection, APR), p= 0.198 (Table 3). The estimated
blood loss in Arm 1 was significantly higher compared with Arm 2, median of 1000 ml
(400ml-2500ml) vs 205 ml (50ml-7000ml), respectively, p= 0.013. However, the number
of patients that received blood transfusion was similar in both Arms, 2 each, p =1.0. The
range of red blood cells packs per patient was .8 (0-4) in Arm 1 vs 0.9 (0-7) in Arm 2,
p=0.933.
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TABLE 2. TRANSLICH STUDY POPULATION CHEMOTHERAPY CHARACTERISTICS
VARIABLE
Chemotherapy characteristics
Chemotherapy prior surgery, n (%)
³ 6 Cycles chemotherapy
Type of chemotherapy
Single Regimen
FOLFOX
Combined regimen
FOLFOX or FOLFIRI /Bevacizumab
Time off chemotherapy prior
to liver resection (days)
Chemo-response, radiology n (%)

ARM 1
ALPPS
N= 7
7(100%)
6 (5-11)

ARM 2
SINGLE STAGE
LIVER RESECTION
N= 10
10 (100%)
5 (1-7)

p= 0.05

NS
0.439

2 (29%)

7 (70%)

5 (71%)

3 (30%)

50 (32-72)

51 (27-184)

0.830

6 (86%)

7 (70 %)

0.338

0.095

Continues variables are expressed as median (IQR). Abbreviations: single regimen, refers to single
regimen either FOLFOX, FOLFIRI; combined regimen, refers to combination either FOLFOX or
FOLFIRI with Bevacizumab.
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TABLE 3. TRANSLICH STUDY POPULATION SURGICAL CHARACTERISTICS
VARIABLE

ARM 1
ALPPS
N= 7

ARM 2
SINGLE STAGE
LIVER
RESECTION
N= 10

Type of liver resection, n (%)
Extended hemihepatectomy
Hemihepatectomy
³ 3 wedges resected

7 (100%)
0
0

0
5 (50%)
5 (50%)

Extrahepatic simultaneous procedures, n (%)
Low Anterior Resection
Abdominal perineal resection

1 (14%)
0

2 (20%)
1 (10%)

p= 0.05

0.002

0.198
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4.1.5. Future Liver Remnant (ALPPS group)
The median interval phase in days between the two stages in the Arm 1 was 9 (7-40
days). Of the 7 patients in Arm 1, the mean %FLR/total liver volume prior the stage one
was 20 ± 2.2. The percentage hypertrophy of FLR/Total liver volume after stage 1 was 35
± 1.6.(Table 4)
4.1.6. Surgical Outcomes
4.1.6.1. Complications
Six of 7 patients in Arm 1 (85%) had post-surgical complications versus 4 of 10 in
Arm 2 (40%), p=0.050. Of these 6 complications in Arm 1, 66% were minor complications
and 17% were major or severe complications, while in Arm 2 these values were, 25%, 50%,
25%, respectively, p=0.405. The total length of hospital stay was significantly higher in
Arm 1 due the fact of two stage procedure, 17.5 days (14-33) in Arm 1 compared with 7
days (4-62 days) in Arm 2, p=0.020 (Table 5).
4.1.6.2. Liver histopathology
R0 resection was presented in 85% of the cases in Arm 1 and 100% of the cases in
Arm 2. The median resection margin was significant higher in Arm 1, 20 mm (8mm -55
mm) compared with Arm 2, 5 mm (1mm-14mm), p= 0.009. Based on the histopathology,
all 7 patients in Arm 1 (100%) showed chemotherapy response, versus only 5 patients
(50%) in Arm 2, p=0.026. Also, the rate of tumour necrosis related with the chemotherapy
response was higher in Arm 1; 80 (75-100) vs 5 (0-100) in Arm 2, p=0.009 (Table 5).
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TABLE 4. LIVER VOLUME ALPPS GROUP
VARIABLE

ARM 1 ALPPS
N= 7

Interval Phase in days, median (range)

9 (7-40)

% Future Liver Remnant/Total liver volume (SD)

20 ± 2.2

% Future Liver Remnant/Total liver volume after stage 1, mean (SD)

35 ± 1.6
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TABLE 5. TRANSLICH STUDY POPULATION POSTOPERATIVE OUTCOMES
VARIABLE
Complications
Any complications, n (%)
Minor complications, Grade £ II
Major complications, Grade IIIa
Severe complications, Grade ³ IIIb

ARM 1
“ALPPS”
N= 7

P= 0.05

6 (85%)

4 (40%)

0.050

4 (66%)
1 (17%)
1 (17%)

1 (25%)
2 (50%)
1 (50%)

0.405

90 days’ mortality
Mortality

0
3/7 (43%)

Total length of hospital stays in days,
Median (range)
Histopathology liver
Margins (mm)
Chemotherapy response, n %
Chemotherapy, tumour necrosis % (range)
R0
R1

ARM 2
SINGLE STAGE
LIVER RESECTION
N= 10

0
2/10 (20%)

NS

17.5 (14-33)

7 (4-62)

0.020

30 (8-55)
7 (100%)
80 (75-100)
6 (85%)
1 (15%)

5 (1-14)
5 (50%)
5 (0-100)
10 (100%)
0

0.009
0.026
0.009
0.411
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4.2. Circulating tumour cells
Evaluation of CTC status in the 24 patients recruited in the study is summarized in
Table 6. Due to logistical challenges, CTCs were only assessed in 2/10 patients prior to the
start of chemotherapy in Arm 1 and in 5/14 patients in Arm 2. The findings showed positive
CTCs in 1 (50%) patient of Arm 1 (1-4 cells), and 3 (50%) patients in Arm 2 (1-6 cells),
p= 0.999. Moreover, assessment of CTC status was performed after completed
chemotherapy for all of the 24 patients recruited in the study; 10/10 patients in Arm 1 and
14/14 in Arm 2. At this time-point, none of the 10 patients in Arm 1 showed positive CTCs
cells, whereas 2/14 (15%) patients in Arm 2 had positive CTCs (1-5 cells), p= 0.266.
Furthermore, one patient with positive CTCs, ³3 (5 cells) in Arm 2 after completion of
chemotherapy was found to have progression of disease on imaging and was therefore
withdraw from the study, p=0.0012 (Table 6).
From the 24 patients that initiated the study, 17 completed liver resection, 7 patients
in Arm 1 and 10 patients in Arm 2, and CTC status was evaluated after stage 1 (time-point
3a) and stage 2 (time-point 3b) in the case of Arm 1, and compared with the control group
of single stage liver resection in Arm 2. Among the 7 patients with CTCs available after
stage 1, two (28.6%) patients had positive CTCs (1-2 cells), and one (17%) patient
presented with positive CTCs (1 cell) after completing both stages. On the other hand, 4
(44%) patients in Arm 2 presented with positive CTC status (1-2 cells), after completed
single staged resection, p=0.286 (Table 6) (Figure 18).
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TABLE 6. Circulating tumour cell assessment of the 24 patients recruited for the study.
Group

Liver metastases

ARM 1

Sync

N of
lesio
ns

Size
prior
chemo
(mm)

1
2
3¯ a
4¯ b
5
6
7
8¯ b
9
10

Yes
Yes
No
No
No
Yes
Yes
Yes
Yes
Yes

4
9
4
3
2
2
7
4
3
3

Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes

5
3
8
3
4
2
2
6
4
2
4
4
2
2

CTCs Time-Points

CEA
(µ/M
L)

#
Chemo
Cycles

Type
of
Chemo

1

20
22
32
26
96
90
45
20
200
20

Size
After
chem
o
(mm
)
18
22
32
26
65
46
25
15
150
17

80
6.2
2
5.4
26
65
102
80
8.3

11
6
3
12
5
6
5
6
6
6

F/B
FX
Cap
FX
FR/B
FX
FX/B
FR
FX/B
FX/B

4
0

14
13
34
85
35
45
16
86
10
30
40
47
48
58

10
18
19
120
35
35
14
49
15
40
40
45
48
58

4.3
4.1
28.1
16
2.3
2.1
4220
4.9
6.6
50
2.0
1.6
.

5
6
6
3
1
7
5
6
1
2
6
6
1
1

FX
FX/B
FX/B
FX
FX
FX
FX
FX/B
FX
Cap
FX
FX/B
FX
FX

ARM 2
11
12
13
14¯ c
15
16
17
18
19
20¯ b
21¯ b
22
23
24¯ c

1
6
1
0
0
2
-

2

0
0
0
0
0
0
0
0
0
0
2
0
2
0
0c
0
0
0
0
0
0
0
0
5c

Outcome

3a

3b

4

Death

0
2
¯
¯
0
0
0
¯
1
0

0
-d
¯
¯
0
0
0
¯
1
0

0
1
¯
¯
0
0
-d
¯
0
0

Yes
YesR
¯
¯
No
No
Yes
¯
No
No

3

4

0
0
No
2
6
YesR
1
0
Yes
¯c
¯c
¯c
0
No
0
0
No
0
0
No
0
0
No
1
0
No
b
b
¯
¯
¯b
b
b
¯
¯
¯b
0
0
No
1
0
No
¯c
¯c
¯c
ARM 1, ALPPS group; ARM 2, Single stage liver resection; Sync, synchronous colorectal liver metastases
(CRLM); n, number of CRLM lesions; size, diameter of the largest CRLM; CEA, carcinoembryonic antigen; #
Chemo, number of chemotherapy cycles before surgery; Type of chemo, FX FOLFOX, FR FOLFIRI, F/B
FOLFOX and Bevacizumab, and Cap; Capecitabine. ¯ withdraw from the study: ¯a Different tumour biology, ¯b
Associated chemotherapy toxicity, ¯c Tumor progression. d Insufficient blood sample, R recurrence and cancer
related-death.
ARM1, Time points blood samples ALPPS: # 1, Pre-Chemotherapy; # 2 Post-Chemotherapy; # 3a, Inter-Stage
ALPPS, # 3b, Post- 2 Stage, # 4, Follow up.
ARM2, Time points blood samples Single liver resection: # 1, Pre-Chemotherapy; # 2, Post-Chemotherapy; #
3, Post-Liver resection; # 4, Follow up.
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Figure 18. Comparison of Circulating tumor cells (CTC) status after chemotherapy (timepoint 2) and after liver resection (time-point 3a and 3b). CTC status was available in 17
patients that underwent for liver resection (7 in ARM-1, and 10 in ARM-2). After stage 1
ALPPS, two patients had CTC positive status (1-2 cells). Among the 6 patients with CTC
status after 2 stage ALPPS, none of the patients with prior CTC negative status were found
positive after completed both stages. On the other hand, from the 10 patients in AMR-2
with CTC status after completed single stage resection, 4 patients were found with CTC
positive status. Number of CTC and status (positive or negative) (y-axis). Time-point of
blood sample collection for (x-axis). Open circles represent ARM-1, whereas open squares
ARM-2.
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The presence of CTCs was evaluated at follow-up (1-2 months after surgery) in the
16 patients with CTC status available. Of the seven patients in Arm 1, one patient who had
positive CTCs after surgery remained positive at follow-up (1 cell). Of the 4 patients in
Arm 2 with positive CTCs after liver resection, only one (12.5%) patient remained with
positive CTC status during follow-up assessment (1-6 cells), p=0.999. In both cases where
CTC positive status remained at follow-up (one patient in each Arm), these patients
developed tumor recurrence, p=0.0083 (Figure 19). Among the 16 patients with CTC
status available at follow-up, eleven (69%) with negative CTC status were found alive
without recurrence and three (19%) patients died. Two (12%) patients with positive CTC
status were found with recurrence and cancer related-death, p=0.0249 (Table 6). Of the
five deaths in the present study, three (43%) deaths were in Arm 1 and two (20%) were in
Arm 2, p=0.592.
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Figure 19. Circulating tumor cells (CTC) assessment after surgery and follow-up. Number of CTC
and status (positive or negative) (y-axis). Time-point of blood sample for both groups (Post-surgery,
and Follow-up) (x-axis). CTC status was available in 16 patients after surgery (circles), open circles;
negative CTC, whereas, blue circles; positive CTC, (1-2 cells). At follow up, CTC status was
available in 15 patients, open squares; negative CTC and recurrence free, while, purple triangle,
positive CTC with recurrence (1-6 cells).
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4.3. MAIT Cells
4.3.1. MAIT cells frequency differences between healthy volunteer’s and
colorectal liver metastases patients.
Initially, to assess whether our population with metastatic cancer presents with a
different frequency of MAIT cells, we decided to compare our colorectal liver metastatic
population with a healthy volunteer. We observed that our patients with CRLM had a
reduced frequency of PBMCs a mean frequency of 3.3% MAIT cells was found, while the
healthy volunteers had a mean of 5.3%. (Figure 20a). This observation was later verified
by MR1Tet staining (Figure 20b). Moreover, we compared the frequency of MAIT cells in
the healthy liver population with the frequency of MAIT cells within the tumour in our
CRLM population. We found a generalized trend towards a reduction in the frequency of
MAIT cells within the tumour, 28% vs 21%, however, this difference did not reach
statistical significance (p = 0.073) (Figure 20c,d).
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Figure 20 a

Figure 20 b

Figure 20 a-b. Graphics comparing the frequency of MAIT cells in the peripheral blood (PBMCS)
among healthy 13 volunteers, and CRLM patients. A series of representative dot-plots depicting two
equivalent gating strategies for identifying MAIT cells by CD3+Va7.2+CD161++ or 5-OP-RU MR-1tet.
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Figure 20 c

Figure 20 d

Figure 20 c-d. Graphics describing the frequency of MAIT cells in the healthy liver volunteers, and
tumor from CRLM patients. A series of representative dotplots depicting two equivalent gating strategies
for identifying MAIT cells by CD3+Va7.2+CD161++ or 5-OP-RU MR-1tet.
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4.3.2. Immunological differences between ALPPS group and single stage live
resection.
To assess whether the liver in the patients undergoing ALPPS (ARM 1) with CRLM
remains immunologically competent, we evaluated the frequency of MAIT cells among
both groups. Thus, we analyzed the frequency of MAIT cells from the total CD3+ within
the peripheral blood (PBMCs), liver, and tumor. Samples were taken during the liver
resection, as described previously (Figure 15-16). Among the 17 patients underwent for
liver resection, 7 blood samples were available in ARM 1, whereas, 9 blood samples were
available in ARM 2 for comparison. We found comparable frequency of MAIT cells in
peripheral blood in both groups. Patients in ARM 1 had a mean frequency of 2.5% MAIT
cells while the patients in ARM 2 had a mean frequency of 2.7 %, p= 0.870. (Figure 21)
Furthermore, we evaluated the frequency of MAIT cells in the liver, as well as the
tumor. Interestingly, there was a trend towards an increase in MAIT cells in the ARM 1
within the liver (28 % vs 17.42%), however, this difference was not statistical significance
(p=0.067), (Figure 22). Then, we observed the frequency of MAIT cells within the tumor.
ARM 1 had a mean frequency of 17.42%, while, ARM 2 had a mean of 10.42 %, p=0.308.
(Figure 23). Altogether, we evaluated and compared whether the frequency of the MAIT
cells was different among both groups (the three compartments), but no significant
difference was observed, p=0.271. Figure.24
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Figure 21. Graphic describing the frequency of MAIT cells in the peripheral blood
(PBMCs) in ARM-1 and ARM 2.

71

Freq. MAIT of CD3+

50
40
30

p=0.067

20
10

2
AR
M

AR
M

1

0

Liver
Figure 22. We evaluated the frequency of MAIT cells in the liver in ARM-1 and ARM-2
of CRLM patients.
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Figure 23. Graphic describing the frequency of MAIT cell within the tumor in
ARM-1 and ARM 2 of CRLM patients.
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Figure 24. Graphic describing the frequency of MAIT cells in: the peripheral blood, liver,
and tumor, between ARM-1 and ARM-2. No significance difference regarding the frequency
of MAIT cells was observed, p=0.271.
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4.3.3. Immunological competency of the liver after chemotherapy treatment
Having noted a large degree of variability in the frequency of MAIT cells, we
wondered what impact the perioperative chemotherapy regimen was having on the
frequency and functionality of MAIT cells. With the majority of patients receiving either
single regimen of chemotherapy with FOLFOX, or combined chemotherapy regimen with
FOLFOX plus bevacizumab (Table 2), thus, we categorized patients based on the regimen
of chemotherapy and evaluated the impact of the number of cycles they received on the
frequency of MAIT cells. To evaluate this, we grouped patients as follow: 1) those that
received FOLFOX (9 patients); 2) those that received FOLFOX + bevacizumab (Avastin)
(8 patients); and 3) a group that received no chemotherapy (5 patients).
Although there was a slight upward trend in the patients who received FOLFOX
alone, there was no correlation between the number of cycles received and the frequency
of MAIT cells in blood (PBMCs), Hepatic MAIT cells (HMNCs), or tumor tissue. (Figure
25a) In contrast, there was a strong negative correlation between the cycle number and
frequency of MAIT cells in the peripheral blood and healthy liver tissue of patients treated
with FOLFOX + bevacizumab (PBMC: r2 = 0.944, p = 0.0057; Liver r2 = 0.915, p = 0.011)
(Figure 25b). While a similar trend was observed in the tumor, this did not reach statistical
significance (r2 = 0.73, p = 0.067) (Figure 25b).
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FOLFOX GROUP

FOLFOX + BEVACIZUMAB
(AVASTIN) GROUP

Figure 25a-25b. The frequency of MAIT cells depicted compared to the number of cycles of
Folfox received (Figure 25a), and Folfox and bevacizumab received (Figure 25 b). r2 and p
values were generated by Pearson analysis. Analyzes in the PBMCs, liver (HMNCs), and tumor
was performed. Frequency of MAIT cells (y- axis), number of cycles (x-axis)
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4.3.3.1. Perioperative chemotherapy fundamentally alters MAIT cell
populations on CRLM patients.
Given the influence of the perioperative chemotherapy on the frequency of MAIT
cells,

and

high

variability

of

activation

observed

following

stimulation,

both inside, and outside the tumor. Interestingly, while the frequency of MAIT cells varied
depending on the perioperative chemotherapy regimen in the peripheral blood and liver,
the responsiveness to stimulation (rIL-12 + rIL-18, SEB, and Klebsiella lystate) was highly
similar in each case (Figure 26 A-C). Moreover, the degree of responsiveness of MAIT
cells within the tumor was highest in the group that received FOLFOX, with individuals
who did not receive chemotherapy showing low levels of activation, and the those who
received FOLFOX + Avastin showing virtually no responsiveness (Figure 26 C).
Unexpectedly, while not significant, both chemotherapy regimens appeared to enhance the
responsiveness of MAIT cells to stimulation with rIL-12 combined with rIL-18, as noted
by the general increase in IFN-g by peripheral blood and liver MAIT cells (Figure 26 A
and B). While a number of individuals that received FOLFOX alone showed some degree
of responsiveness in the tumor, in contrast, MAIT cells within the tumor (with only one
exception) of those who received FOLFOX + bevacizumab demonstrated a complete lack
of a response (Figure 26 C). Interestingly, this patient was the only individual to receive
FOLFOX + Avastin that did not achieve any tumor necrosis, which was typically greater
than 75% (data not shown). While this provides a likely explanation for the increased
responsiveness in this individual, it remains to be seen what impact tumor necrosis has on
the activation or survival of MAIT cells.
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Figure 26 A-C. Differential effect of chemotherapy on the function of MAIT cells in
CRLM patients.

Figure 26 A-C. Describes how patients who had received no chemotherapy, Folfox alone, or Folfox +bevacizumab responded
to stimulation with a panel of MAIT cell mitogens. (A) Left - the frequency of IFN-g production by PBMC MAIT cells in
response to medium, rIL-12 +rIL-18, SEB, or Klebsiella lysate. Right – The frequency of PBMC MAIT cells producing IFN-g
in response to rIL-12 +rIL-18 is depicted compared to the number of cycles of Folfox or Folfox + bevacizumab received; (B)
Left - the frequency of IFN-g production by HMNCs MAIT cells in response to medium, rIL-12 +rIL-18, SEB, or Klebsiella
lysate. Right – The frequency of HMNCs MAIT cells producing IFN-g in response to rIL-12 +rIL-18 is depicted compared to
the number of cycles of Folfox or Folfox + bevacizumab received; (C) Left - the frequency of IFN-g production by tumor
MAIT cells in response to medium, rIL-12 +rIL-18, SEB, or Klebsiella lysate. Right – The frequency of tumor MAIT cells
producing IFN-g in response to rIL-12 +rIL-18 is depicted compared to the number of cycles of Folfox or Folfox + bevacizumab
received.

78
CHAPTER 5
5. DISCUSSION
5.1. ALPPS
ALPPS has emerged as a novel surgical approach with the potential to improve the
likelihood of resectability, specifically in those patients with extensive cancer disease and
a small FLR. The two major ALPPS advantages are: rapid liver kinetic growth, and surgical
complete resection of all disease compared to the conventional two-staged hepatectomy
with PVE. (70)
These proposed advantages of ALPPS have been counterbalanced by reports of high
perioperative morbidity and mortality. The first published cohort described a 12%
perioperative mortality rate (78), with other studies reporting similarly high perioperative
mortality as well as severe morbidity in up to two-thirds of patients (79). Our single-center
experience with ALPPS demonstrates consistently acceptable morbidity and no
perioperative mortality throughout the study period. Our group has previously published
an early experience with ALPPS, demonstrating no 90-day mortality in a pilot series of 14
patients (80). In this short cohort, we again report no 90-day mortality in 7 patients, with a
66% minor complication (Clavien-Dindo £ II) rate.

5.2. Circulating tumor cells “CTCs”
Circulating tumour cells have been shown to represent the concentration of cancer
cells in the blood circulation.(81,82) Furthermore, the presence of ³3 CTCs has been
associated with poor prognosis in patients with metastatic colorectal cancer. (81–83)
Therefore, the research community has investigated their utility to serve as potential
surrogate markers for early treatment response, by associating their presence and
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elevation with disease recurrence or progression, with promising results. (83,84)
Accordingly, in our current investigation, we chose it as an evaluation tool to assess if the
rapid and extensive hypertrophy that occurs during the ALPPS procedure for treatment of
colorectal liver metastasis results in increased tumor cells dissemination and disease

progression.
We evaluated the positivity and levels of circulating tumour cells at different timepoints during the treatment. After completion of chemotherapy the presence of CTCs was
assessed, and of the two patients with positive CTCs, the one who had ³3 CTCs was
withdrawn from the study due to disease progression. This finding correlates with other
reports and confirms the prognostic value for disease progression at this CTC cutoff.(61,82) Moreover, CTCs were evaluated at the time of surgery (after first and second
stage ALPPS) and compared with the control group (single stage major liver resection) to
whether rapid hypertrophy results in tumor cells dissemination. The present results show
that intraoperative mobilization of the liver and tumor, portal vein ligation, and liver
partition with subsequently accelerated, and extensive liver hypertrophy, do not release or
increase the CTCs after first and second stages of ALPPS, based on no significant
difference in CTC compared with the control group. Since the 2 Arms were comparable
with respect to the tumour load, these results should be considerable. However, no recent
report has evaluated ALPPS at such situation that can reinforce and validate our
information.
Two staged hepatectomy with PVE has been used as an standard procedure to
provide increased hypertrophy in patients with insufficient FLR requiring extensive liver
resection. However, 20-30% of the patients do not reach the second staged due to tumor
progression.(26) Interesting observations were made by a group of Norway (2), when CTCs
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were assessed at surgery after two-staged liver resection with PVE in CRLM patients, it
was observed that levels of CTCs where higher after the second staged, and these patients
has worse DFS and OS in their population of study. Contrary to their findings, our results
showed that ALPPS might provide better outcomes and less tumour cell dissemination.
This might be explained by the shorter period of inter-staged waiting time, 7-10 days for
ALPPS, compared with the 6-8 weeks during the classical two-staged hepatectomy with
PVE, which could increase the time for tumor cell growth. (85–87)
In our study, we also evaluated the presence of CTCs at 1-2 months’ follow-up postsurgery, observing that all patients that remained with negative CTC status did not present
with tumour recurrence, whereas the two patients who had showed positive CTCs had
detectable recurrence. Interestingly, both remained positive during all time-points of the
study. Furthermore, both patients with persistence and positivity of CTCs had cancerrelated death. This interesting association supports what other groups have reported in other
types of cancers, (88) and suggests that persistence of positivity of circulating tumour cells
might have an impact on prognosis and patient outcomes.
Another important observation in our results is related to the levels of CTCs.
Whereas others groups have reported a cut-off for better or worse outcomes (<3 or ³3 CTC
in a 7.5 mL CTC/blood sample blood sample)(60,82). We observed that the presence and
persistence of ³1 circulating tumour cells was correlated with worse prognosis. This
indicates that, an ideal cut-off in metastatic colorectal cancer remains undetermined.
In conclusion, in our present investigation detection of CTC serves as an important
tool of prognostic value in patients undergoing for ALPPS for colorectal liver metastasis.
These findings suggest firstly that accelerated and extensive hypertrophy was not
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associated with more release of cancer cells and subsequently disease progression.
Secondly, persistence and positivity of CTC at follow-up was significantly associated with
disease progression. Nevertheless, due the small sample size and short follow-up, our
results should be taken carefully. Further follow-up combined with serial analysis of CTCs
should be considered for future investigation.
5.3. MAIT cells
The ALPPS approach results in an accelerated and extensive hypertrophy of the
FLR. However, limited evidence exists regarding the immunological competence of the
FLR, particularly in patients with CRLM. The liver represents a unique immunological
organ dominated by innate-like T lymphocytes. Recently, it has been shown that a mucosaassociated invariant T cell population comprise 30%-50% of the total hepatic T
lymphocytes. (42,45) MAIT cells are innate-like T lymphocytes that express the invariant
TCRa (iTCRa) chain TRAV1-2-TRAJ33 (Vα7.2-Jα33 in humans) (89,90) and produce a
plethora of pro- and/or anti-inflammatory cytokines (e.g., IFN-g, TNF-a, IL-17, IL-4, and
IL-10) and various granzymes (A, B, K ,and M) when activated (91,92). Given this
particularity of MAIT cells, their high proportion within the liver microenvironment, and
their potential role during the liver immune response, thus, we wondered whether their
frequency and functionality was affected during ALPPS and perioperative chemotherapy.
Despite their abundance both in the liver and at other mucosal sites, the role of
MAIT cells in tumor surveillance remains largely unknown. Initially, to elucidate the role
of MAIT cells in CRLM patients, we compared our CRLM patients with a healthy group
of volunteers. We evaluated the MAIT cells frequency from the total CD3+ PBMCs, and
their capacity to be activated by a panel of agonists in both groups. Interestingly, and in
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contrast to the findings of other studies, in which the frequency of the MAIT cells in the
peripheral blood of cancer patients did not change (93), we observed a significant reduction
in MAIT cells frequency in the peripheral blood. Moreover, we observed a trend towards a
reduction in the frequency of MAIT cells within the tumor.
Observing this variability of the frequency of the MAIT cells, we wondered if the
MAIT cells frequency exhibits different proportion in the ALPPS group. In a recent ALPPS
cohort published by our group (77), we demonstrate that the ALPPS liver appears to
maintain its immune distribution, and that the liver cell composition of the FLR during the
extensive and accelerated hypertrophy remains constant. Also, we found the liver cell
populations proportion including CD4+ T cells, NKT cells, B cells, Kupffer cells, and
including the MAIT cells increased significantly. In our current investigation, we focused
on MAIT cells, and found that MAIT cells frequency in the peripheral blood (PBMCs)
remains similar, but their proportion in the liver showed a trend towards increasing
compared with the control group. These findings enhance, and validate our prior
investigation(77), where we concluded that, while accelerated and extensive hypertrophy
occurs within the FLR in the ALPPS population, an expansion of hepatic immune cells
results as well.
Altogether, MAIT cell frequency in the liver of CRLM population is reduced
compare with the healthy volunteers, but higher in those who underwent an ALPPS
resection. This might be explained by the immune system activation, as a consequence of
the inflammatory mechanism of the ALPPS resulting in rapid hypertrophy of the FLR,
therefore suggesting an homogeneous immune cell restoration.
Furthermore, although we observed an increase in MAIT cells frequency in the liver
in the ALPPS group, we observed a suppression in their frequency within the tumour in
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both groups, thus, we wondered whether this variability may be due the influence of the
perioperative type of chemotherapy. As such, we aimed to determine whether the different
type of regimens had an impact on the frequency and functionality of MAIT cells, both
inside and outside the tumor. We observed a slight upward trend in the frequency of MAIT
cells in the patients who received FOLFOX alone, but no correlation between the number
of cycles received or the frequency of MAIT cells in PBMCs, liver, or tumor tissue was
found. On the other hand, a strong negative correlation between the cycle number and
frequency of MAIT cells in the peripheral blood and healthy liver tissue of patients treated
with FOLFOX + bevacizumab was observed.
Our observation with respect to the association of responsiveness of the immune
response with FOLFOX therapy is similar to what has been reported by other authors
(94,95). During the latest report from the randomised control trial EORTC in 2015 (94),
whether the immune response in CRLM was influenced by systemic therapy was
investigated and was related with patient disease free survival. In particular, the
investigators evaluated liver resection alone or with the addition of FOLFOX therapy.
Interestingly, in the group treated with FOLFOX, they observed and increase in the CD3+
lymphocytes and mast cells inside the tumor, demonstrating a correlation between high
CD3+ response and pathological response. This was also related to an improvement in the
disease free survival. A similar association was also reported by Halama et al,
demonstrating a highly density of CD3+, CD+8, and granzyme B+ T cells within the tumor
margins of CRLM patients treated with FOLFOX therapy, and associated this with longer
disease free and overall survival.(95)
An explanation of how chemotherapy affects the immune response was offered by
Zitovogel et al. Their hypothesis involves transitional mechanisms of lymphopenia,
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followed by a high stimulation of more tumour infiltrating T-cells, thereby favoring
chemokine attraction into the tumor, with subsequent tumor cell death. (94,96)
In contrary to the findings in the FOLFOX, the combined regimen group
experienced a decrease in MAIT cells frequency, and a lack of responsiveness after
stimulation in those patients with more than 75 % of tumor necrosis. It is perplexing that
the addition of bevacizumab a monoclonal antibody against a vascular endothelial growth
factor (VEGF), could so drastically effect the frequency of MAIT cells. One explanation
could be related to the regulation of the multidrug resistance gene 1 (MDR1), an ABC
transporter known to provide MAIT cells with resistance to chemotherapy (44,93,97).
Specifically, there have been reports that VEGF can induce the expression of MDR1 in
various cell types (98). It remains plausible that MDRI expression by MAIT cells may be
partially dependent on VEGF.
Together, these results showed that chemotherapy affects the liver immune
response, depending of the type of chemotherapy regimen received. The findings suggest
that FOLFOX therapy has immunostimulatory effects in the liver, while bevacizumab
therapy leads to tumor necrosis with immunosuppressive side effects within the tumor.
Each regimen seems to act in different pathway, and their therapeutics efficacy should be
interpreted independently, giving the concept that chemotherapy should stimulate the
immune response. Thus, the liver immune activation or suppression within the tumor may
result underestimation of the regimen response.
Although convincing, given the small sample size, a larger cohort is needed to
validate these findings. Moreover, longer follow up is necessary to evaluated whether this
variability in the responsiveness of the chemotherapy might have a prognostic impact.
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